title: Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus.
authors.forename: H
authors.initials: H
authors.lastname: Nakase
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Matsuura
authors.forename: Y
authors.initials: Y
authors.lastname: Honzawa
authors.forename: T
authors.initials: T
authors.lastname: Chiba
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003587:Cytomegalovirus; D006801:Humans; D000069285:Infliximab; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D016559:Tacrolimus